The effect of SNPs in CYP450 in chloroquine/primaquine Plasmodium vivax malaria treatment

BACKGROUND: Chloroquine/primaquine is the current therapy to eliminate Plasmodium vivax infection in the Amazon region. AIMS: This study investigates CYP1A2, CYP2C8, CYP2C9, CYP3A4 and CYP3A5 genetic polymorphisms influence on cloroquine/primaquine treatment. PATIENTS & METHODS: Generalized esti...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Pharmacogenomics
Glavni autori: Sortica, Vinicius A, Lindenau, Juliana D, Cunha, Maristela G, Ohnishi, Maria DO, Ventura, Ana Maria R, Ribeiro-dos-Santos, Ândrea KC, Santos, Sidney EB, Guimarães, Luciano SP, Hutz, Mara H
Format: Artigo
Jezik:Inglês
Izdano: Future Medicine Ltd 2016
Teme:
Research Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7099632/
https://ncbi.nlm.nih.gov/pubmed/27767381
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2217/pgs-2016-0131
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items